medsovetМедицинский СоветMeditsinskiy sovet = Medical Council2079-701X2658-5790REMEDIUM GROUP Ltd.10.21518/2079-701X-2017-20-182-187medsovet-2252Research ArticleГИНЕКОЛОГИЯGYNECOLOGYГОРМОНАЛЬНАЯ КОНТРАЦЕПЦИЯ КАК МЕТОД ЛЕЧЕНИЯ ЖЕНЩИН С АНОМАЛЬНЫМИ МАТОЧНЫМИ КРОВОТЕЧЕНИЯМИHORMONAL CONTRACEPTION AS TREATMENT FOR ANOMALOUS UTERINE BLEEDINGКузнецоваИ. В.KuznetsovaI. V.

доктор медицинских наук, профессор.

Москва.

 MD, Prof.

Moscow.

Первый Московский государственный медицинский университет им. И.М. Сеченова.РоссияSechenov First Moscow State Medical University.Russian Federation201707012018020182187Copyright © Кузнецова И.В., 20182018Кузнецова И.В.Kuznetsova I.V.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-sovet.pro/jour/article/view/2252

Аномальные маточные кровотечения (АМК) являются распространенной патологией у женщин репродуктивного возраста. В обзоре представлены современная классификация и терминология АМК, рассмотрены основные причины и механизмы возникновения кровотечений. Гормональная контрацепция успешно используется с целью контроля менструального цикла у сексуально активных женщин. В статье приводятся данные исследований, посвященных вопросам применения гормональных контрацептивов, оцениваются возможности использования гормональных противозачаточных средств в терапии АМК, обусловленных различными заболеваниями, дается характеристика гормональных противозачаточных средств, имеющих хорошую доказательную базу применения у женщин с АМК различного происхождения, нуждающихся в предохранении от нежеланной беременности.

Abnormal uterine bleeding (AMC) is a common pathology in women of childbearing age. The review gives the current classification and terminology of AMC, the main causes and mechanisms involved in bleeding. Hormonal contraception has been successfully used to control the menstrual cycle in sexually active women. The article is intended to provide research data on the use of hormonal contraceptives, assess the use of hormonal contraceptives in AMC therapy caused by various diseases, and describe the characteristics of evidence-based hormonal contraceptives to be used by women with AMC of various origins who need protection against unwanted pregnancy.

аномальные маточные кровотеченияобильные (тяжелые) менструальные кровотеченияановуляцияэндометрийгиперплазия эндометрияконтроль менструального циклагормональная контрацепциякомбинированные оральные контрацептивыдиеногест/эстрадиола валератabnormal uterine bleedingheavy (heavy) menstrual bleedinganovulationendometriumendometrial hyperplasiamenstrual cycle controlhormonal contraceptioncombined oral contraceptivesdienogest/estradiol valerateReferencesACOG Practice bulletin No. 128: Diagnosis of Abnormal Uterine Bleeding in ReproductiveAged Women. Obstet Gynecol, 2012, 120(1): 197–206.ACOG Practice bulletin No. 128: Diagnosis of Abnormal Uterine Bleeding in ReproductiveAged Women. Obstet Gynecol, 2012, 120(1): 197–206.Garza-Cavazos AJ, Loret de Mola R. Abnormal Uterine Bleeding New Definitions and Contemporary Terminology. Female Patient, 2012, 37.Garza-Cavazos AJ, Loret de Mola R. Abnormal Uterine Bleeding New Definitions and Contemporary Terminology. Female Patient, 2012, 37.Heavy menstrual bleeding. Clinical guideline No. 44. London National Institute for Health and Clinical Excellence, 2017.Heavy menstrual bleeding. Clinical guideline No. 44. London National Institute for Health and Clinical Excellence, 2017.Bonafede MM, Miller JD, Lukes AS et al. Retrospective database analysis of clinical outcomes and costs for treatment of abnormal uterine bleeding among women enrolled in US Medicaid programs. Clinin Econom Outcom Res, 2014, 6: 423–429.Bonafede MM, Miller JD, Lukes AS et al. Retrospective database analysis of clinical outcomes and costs for treatment of abnormal uterine bleeding among women enrolled in US Medicaid programs. Clinin Econom Outcom Res, 2014, 6: 423–429.Jensen JT, Lefebvre P, Laliberté F, et al. Cost burden and treatment patterns associated with management of heavy menstrual bleeding. J Womens Health (Larchmt), 2012, 21: 539–547.Jensen JT, Lefebvre P, Laliberté F, et al. Cost burden and treatment patterns associated with management of heavy menstrual bleeding. J Womens Health (Larchmt), 2012, 21: 539–547.Gayle MS, Tarin A, Dalton S, Weiss PM, Madsen KP. Evaluation and Management of Abnormal Uterine Bleeding in Premenopausal Women. Am Fam Physician, 2012, 85(1).Gayle MS, Tarin A, Dalton S, Weiss PM, Madsen KP. Evaluation and Management of Abnormal Uterine Bleeding in Premenopausal Women. Am Fam Physician, 2012, 85(1).Munro MG, Critchley HO, Broder MS, Fraser IS. FIGO classification system (PALM-COEIN) for causes of abnormal uterine bleeding in nongravid women of reproductive age. Int J Gynaecol Obstet, 2011, 113(1): 3–13.Munro MG, Critchley HO, Broder MS, Fraser IS. FIGO classification system (PALM-COEIN) for causes of abnormal uterine bleeding in nongravid women of reproductive age. Int J Gynaecol Obstet, 2011, 113(1): 3–13.Davies J, Kadir RA. Endometrial haemostasis and menstruation. Rev Endocr Metab Disord, 2012, 13(4): 289–299.Davies J, Kadir RA. Endometrial haemostasis and menstruation. Rev Endocr Metab Disord, 2012, 13(4): 289–299.ACOG Practice Bulletin No. 136: Management of Abnormal Uterine Bleeding Associated With Ovulatory Dysfunction. Obstet Gynecol, 2013, 122: 176-185.ACOG Practice Bulletin No. 136: Management of Abnormal Uterine Bleeding Associated With Ovulatory Dysfunction. Obstet Gynecol, 2013, 122: 176-185.Faculty of Sexual & Reproductive Healthcare Clinical Guidance. Contraception for women aged over 40 years. 2010.Faculty of Sexual & Reproductive Healthcare Clinical Guidance. Contraception for women aged over 40 years. 2010.Sasagawa S, Shimizu Y, Kami H, et al. Dienogest is a selective progesterone receptor agonist in transactivation analysis with potent oral endometrial activity due to its efficient pharmacokinetic profile. Steroids, 2008, 73: 222-231.Sasagawa S, Shimizu Y, Kami H, et al. Dienogest is a selective progesterone receptor agonist in transactivation analysis with potent oral endometrial activity due to its efficient pharmacokinetic profile. Steroids, 2008, 73: 222-231.Farquhar C, Brown J. Oral contraceptive pills for heavy menstrual bleeding. Cochrane Database Syst Rev, 2009, 4: CD002120.Farquhar C, Brown J. Oral contraceptive pills for heavy menstrual bleeding. Cochrane Database Syst Rev, 2009, 4: CD002120.Endricat J, Shapiro H, Luccari-Lax E, Kunz M, Schmidt W, Fortier MA. Canadian, multicentre study comparing the efficacy of a levonorgestrel-releasing intrauterine system to an oral contraceptive in women with idiopathic menorrhagia. J Obstet Gynaecol Can, 2009, 31: 340347.Endricat J, Shapiro H, Luccari-Lax E, Kunz M, Schmidt W, Fortier MA. Canadian, multicentre study comparing the efficacy of a levonorgestrel-releasing intrauterine system to an oral contraceptive in women with idiopathic menorrhagia. J Obstet Gynaecol Can, 2009, 31: 340347.National Institute for Health and Clinical Excellence. Heavy Menstrual Bleeding (NICE Clinical Guideline 44). 2007.National Institute for Health and Clinical Excellence. Heavy Menstrual Bleeding (NICE Clinical Guideline 44). 2007.Micks EA, Jensen JT. Treatment of Heavy Menstrual Bleeding with the Estradiol Valerate and Dienogest Oral Contraceptive Pill. Adv Ther, 2012, 12.Micks EA, Jensen JT. Treatment of Heavy Menstrual Bleeding with the Estradiol Valerate and Dienogest Oral Contraceptive Pill. Adv Ther, 2012, 12.Nappi RE, Serrani M, Jensen JT. Noncontraceptive benefits of the estradiol valerate/dienogest combined oral contraceptive: a review of the literature. Int J Womens Health, 2014, 6: 711–718.Nappi RE, Serrani M, Jensen JT. Noncontraceptive benefits of the estradiol valerate/dienogest combined oral contraceptive: a review of the literature. Int J Womens Health, 2014, 6: 711–718.Poromaa IS. Estradiol valerat combined with dienogest: a new concept contraceptive pill for women with heavy menstrual bleeding. Gynecol Forum, 2011, 16(1): 10–13.Poromaa IS. Estradiol valerat combined with dienogest: a new concept contraceptive pill for women with heavy menstrual bleeding. Gynecol Forum, 2011, 16(1): 10–13.Ahrendt HJ, Makalova D, Parke S, et al. Bleeding pattern and cycle control with an estradiolbased oral contraceptive: a seven-cycle, randomized comparative trial of estradiol valerate/ dienogest and ethinyl estradiol/levonorgestrel. Contraception, 2009, 80: 436–444.Ahrendt HJ, Makalova D, Parke S, et al. Bleeding pattern and cycle control with an estradiolbased oral contraceptive: a seven-cycle, randomized comparative trial of estradiol valerate/ dienogest and ethinyl estradiol/levonorgestrel. Contraception, 2009, 80: 436–444.Jensen JT, Machlitt A, Mellinger U, et al. A multicenter, double-blind, randomized, placebocontrolled study of oral estradiol valerate/dienogest for the treatment of heavy and/or prolonged menstrual bleeding. Fertil Steril, 2009, 93(suppl 3): S32.Jensen JT, Machlitt A, Mellinger U, et al. A multicenter, double-blind, randomized, placebocontrolled study of oral estradiol valerate/dienogest for the treatment of heavy and/or prolonged menstrual bleeding. Fertil Steril, 2009, 93(suppl 3): S32.Fraser IS, Zeun S, Machlitt A, Mellinger U. A novel oral contraceptive comprising estradiol valerate/dienogest for the treatment of heavy and/or prolonged menstrual bleeding without organic cause a double-blind, randomized, placebo-controlled trial. Int J Gynecol Obstet, 2009, 107(suppl 2): S183.Fraser IS, Zeun S, Machlitt A, Mellinger U. A novel oral contraceptive comprising estradiol valerate/dienogest for the treatment of heavy and/or prolonged menstrual bleeding without organic cause a double-blind, randomized, placebo-controlled trial. Int J Gynecol Obstet, 2009, 107(suppl 2): S183.Кузнецова И.В. Возможности терапии гиперпластических процессов эндометрия. Трудный пациент, 2010, 1-2: 117–126.Кузнецова И.В. Возможности терапии гиперпластических процессов эндометрия. Трудный пациент, 2010, 1-2: 117–126.Calaf-Alsina J. Mastering menstruation: a challenge for hormonal contraception. Gynecol Forum, 2011, 16(1): 3.Calaf-Alsina J. Mastering menstruation: a challenge for hormonal contraception. Gynecol Forum, 2011, 16(1): 3.Epplein M, Reed SD, Voigt LF, et al. Endometrial Hyperplasia Risk in Relation to Recent Use of Oral Contraceptives and Hormone Therapy. Ann Epidemiol, 2009, 19(1): 1–7.Epplein M, Reed SD, Voigt LF, et al. Endometrial Hyperplasia Risk in Relation to Recent Use of Oral Contraceptives and Hormone Therapy. Ann Epidemiol, 2009, 19(1): 1–7.Hannaford PC, Selvaraj S, Elliot AM, Angus V, Iversen L, Lee AG. Cancer risk among users of oral contraceptive: cohort data from the Royal College of General Practitioner`s oral contraceptive study. BMJ, 2007, 335: 651.Hannaford PC, Selvaraj S, Elliot AM, Angus V, Iversen L, Lee AG. Cancer risk among users of oral contraceptive: cohort data from the Royal College of General Practitioner`s oral contraceptive study. BMJ, 2007, 335: 651.Klipping C, Junge W, Mellinger U. Haemostatic effects of a novel four-phasic combined oral contraceptive containing estradiol valerate and dienogest. Eur J Contracept Reprod Health Care, 2008, 13: 96-97.Klipping C, Junge W, Mellinger U. Haemostatic effects of a novel four-phasic combined oral contraceptive containing estradiol valerate and dienogest. Eur J Contracept Reprod Health Care, 2008, 13: 96-97.Fraser IS, Rӧmer T, Parke S, Zeun S, Mellinger U, Machlitt A, Jensen JT. Effective treatment of heavy and/or prolonged menstrual bleeding with an oral contraceptive containing estradiol valerate and dienogest: a randomized, doubleblind Phase III trial. Human Reproduction, 2011, 26(10): 2698-2708.Fraser IS, Rӧmer T, Parke S, Zeun S, Mellinger U, Machlitt A, Jensen JT. Effective treatment of heavy and/or prolonged menstrual bleeding with an oral contraceptive containing estradiol valerate and dienogest: a randomized, doubleblind Phase III trial. Human Reproduction, 2011, 26(10): 2698-2708.Медицинские критерии приемлемости методов контрацепции РФ. Адаптированный документ «Медицинские критерии приемлемости использования методов контрацепции ВОЗ». 4-е изд., 2009. М., 2012.Медицинские критерии приемлемости методов контрацепции РФ. Адаптированный документ «Медицинские критерии приемлемости использования методов контрацепции ВОЗ». 4-е изд., 2009. М., 2012.

The authors declare that there are no conflicts of interest present.